| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1043941904 |
| P356 | DOI | 10.1186/GM482 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/gm482 |
| P932 | PMC publication ID | 3978667 |
| P698 | PubMed publication ID | 24004612 |
| P5875 | ResearchGate publication ID | 256448193 |
| P50 | author | Lorraine A Chantrill | Q55149800 |
| Mark Pinese | Q55167830 | ||
| Nicola J Waddell | Q60503046 | ||
| Jian-min Wu | Q82105421 | ||
| Ann-Marie Patch | Q82398972 | ||
| Ilse Rooman | Q83181310 | ||
| Adnan Nagrial | Q96227552 | ||
| David K Miller | Q112847752 | ||
| Marina Pajic | Q38802477 | ||
| Mark J. Cowley | Q38802512 | ||
| Sean Grimmond | Q38802553 | ||
| Andrew Biankin | Q38802580 | ||
| David K Chang | Q43966083 | ||
| P2093 | author name string | John V Pearson | |
| David Goldstein | |||
| Anthony J Gill | |||
| Karin S Kassahn | |||
| Harpreet Wasan | |||
| Angela Chou | |||
| Christopher W Toon | |||
| Elizabeth A Musgrove | |||
| Katia Nones | |||
| Amber L Johns | |||
| Jaswinder S Samra | |||
| Jeremy Humphris | |||
| Adrienne L Morey | |||
| R Scott Mead | |||
| Venessa Chin | |||
| P2860 | cites work | Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. | Q52297317 |
| Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. | Q53149260 | ||
| Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes | Q24595981 | ||
| Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 | ||
| International network of cancer genome projects | Q24611474 | ||
| DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. | Q27851466 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Cancer statistics, 2010 | Q27860525 | ||
| Supervised risk predictor of breast cancer based on intrinsic subtypes | Q29617404 | ||
| HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy | Q33517907 | ||
| The BATTLE trial: personalizing therapy for lung cancer | Q34275011 | ||
| The prognostic and predictive value of serum CA19.9 in pancreatic cancer | Q34635104 | ||
| Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer | Q35832274 | ||
| Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. | Q36212421 | ||
| Her2-targeted therapies in non-small cell lung cancer | Q36542431 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| Somatic variation and cancer: therapies lost in the mix. | Q37885276 | ||
| The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma | Q37969932 | ||
| Metastatic behavior of breast cancer subtypes | Q38416421 | ||
| Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future | Q39895216 | ||
| Margin clearance and outcome in resected pancreatic cancer | Q39984329 | ||
| Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine | Q40242682 | ||
| Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). | Q40809042 | ||
| Superhighway or blind alley? The cancer genome atlas releases first results. | Q42589302 | ||
| Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu | Q45174616 | ||
| Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. | Q46925466 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 78 | |
| P577 | publication date | 2013-08-31 | |
| P1433 | published in | Genome Medicine | Q15816848 |
| P1476 | title | Clinical and molecular characterization of HER2 amplified-pancreatic cancer | |
| P478 | volume | 5 |
| Q35903727 | A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. |
| Q60924652 | Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression |
| Q38694488 | Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer |
| Q34248282 | Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers |
| Q56543306 | Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence? |
| Q99614738 | Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities |
| Q57422490 | Can we move towards personalised pancreatic cancer therapy? |
| Q38730160 | Cellular and molecular aspects of pancreatic cancer |
| Q91695476 | Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer |
| Q45063614 | Clinical study of genomic drivers in pancreatic ductal adenocarcinoma |
| Q58610296 | Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine |
| Q48221094 | Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. |
| Q91344944 | Development and validation of a targeted gene sequencing panel for application to disparate cancers |
| Q91595228 | Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma |
| Q35828693 | Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial |
| Q58106214 | Enrichment of Amplification in Brain Metastases from Primary Gastrointestinal Malignancies |
| Q35987242 | Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma |
| Q34302954 | Gene therapy in pancreatic cancer |
| Q36336091 | Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability. |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q55073226 | Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. |
| Q50584924 | Mining the genomes of exceptional responders. |
| Q33624574 | Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward |
| Q34177065 | Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer |
| Q91341271 | Molecular subtypes of pancreatic cancer |
| Q54277914 | Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong? |
| Q92912017 | Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal |
| Q38396634 | Pancreatic cancer: from state-of-the-art treatments to promising novel therapies |
| Q26799714 | Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies |
| Q33801384 | Personalising pancreas cancer treatment: When tissue is the issue |
| Q38653309 | Pertuzumab in gastrointestinal cancer |
| Q91620888 | Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer |
| Q36600002 | Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis |
| Q37617965 | Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer |
| Q53636755 | Role of vitamin D receptor gene polymorphisms in pancreatic cancer: a case-control study in China. |
| Q53229089 | SOX9 regulates ERBB signalling in pancreatic cancer development. |
| Q90208114 | Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review |
| Q57105900 | Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer |
| Q36000813 | Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. |
| Q90682184 | The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA |
| Q35875608 | The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas |
| Q37291876 | Ultra-Specific Isolation of Circulating Tumor Cells Enables Rare-Cell RNA Profiling |
Search more.